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The human T-cell leukemia virus type I (HTLV-I) Tax protein and the hepatitis B virus (HBV) X protein have each been
shown to activate transcription of their respective viral promoters as well as a subset of cellular gene promoters. Here we
show that the HTLV-I long terminal repeat (LTR) is responsive to HBV X transactivation. Maximum levels of X-mediated
transactivation of the LTR were 8-fold. An X-responsive-region (XRR) of the LTR is located between nucleotides 0355 and
0276 and contains an AP-2 binding site, a previously recognized X-responsive element. We demonstrated that Tax and X
synergize to activate transcription from the HTLV-I LTR, although the AP-2 binding site was not required for this synergy.
These results raise the possibility that the HBV X protein may affect the level of HTLV-I gene expression in co-infected
individuals. q 1996 Academic Press, Inc.
INTRODUCTION ing three copies of a 21-basepair repeat known as Tax
responsive element 1 (TRE-1). Two or more copies of
Human T-cell leukemia virus type I (HTLV-I) and hepati- TRE-1 are necessary to confer Tax responsiveness to a
tis B virus (HBV) both cause human diseases character- promoter. Multimerized copies of TRE-1 are also respon-
ized by long latency periods. HTLV-I is the etiologic agent sive to the mitogens TPA and cAMP, and TRE-1 contains
of adult T-cell leukemia (ATL) and tropical spastic para- a core element which resembles a CRE. TRE-1 has been
paresis/HTLV-I-associated myelopathy (TSP/HAM) (Ges- shown to bind cellular transcription factors which are
sain et al., 1985; Hinuma et al., 1982; Poiesz et al., 1980; members of the CRE-binding (CREB) and ATF protein
Posner et al., 1981; Yoshida et al., 1982), whereas chronic families. Further, Tax has been shown to form a physical
infection with HBV has been associated with an in- complex with CREB and ATF (Suzuki et al., 1993; Wagner
creased risk of developing hepatocellular carcinoma and Green, 1993; Zhao and Giam, 1991, 1992). A single
(Beasley et al., 1981; Buendia, 1992; Slagle et al., 1992; copy of the second Tax-responsive element, TRE-2, is
Szmuness, 1978). Both HTLV-I and HBV can infect T lym- located between 0117 and 0163 in the LTR. Multimer-
phocytes (Davison et al., 1987; Pasquielli et al., 1986) ized copies of TRE-2 are not Tax responsive, but a single
and it is known that certain patients are co-infected with copy of TRE-2 in combination with a single copy of TRE-
both viruses (Asakura et al., 1991; Yamaguchi et al., 1 confers Tax responsiveness to a promoter. TRE-2 con-
1993). It is possible that co-infected individuals might tains binding sites for Sp1, Myb, Ets1, NF-kB, and a 36-
display a more aggressive disease progression. kDa protein (Bosselut et al., 1990, 1992; Gitlin et al., 1991;
HTLV-I encodes a nonstructural protein, Tax, which is Marriott et al., 1990; Numata et al., 1991; Nyborg et al.,
a powerful transcriptional transactivator and is the trans- 1990). Tax has been shown to form a protein–protein
forming protein of this virus (reviewed in Sodroski, 1992). complex with the 36-kDa protein (Marriott et al., 1990)
Tax activates transcription of the HTLV-I long terminal and can cooperate with Ets1 in transactivation of the LTR
repeat (LTR), as well as a variety of cellular gene promot- (Gitlin et al., 1993).
ers. At least three different Tax-responsive elements HBV encodes a 17-kDa nonstructural protein, X, which
have been identified in these promoters, including cAMP can transactivate transcription from many viral and cellu-
response element (CRE)/activating transcription factor lar promoters (Avantaggiati et al., 1992; Levrero et al.,
(ATF), serum response element (SRE), and nuclear factor 1990; Menzo et al., 1993; Rossner, 1992; Seto et al., 1988;
kB (NF-kB) sites. Siddiqui et al., 1989; Spandau and Lee, 1988; Twu and
Regulation of HTLV-I transcription is complex and in- Schloemer, 1987; Twu and Robinson, 1989; Twu et al.,
volves numerous cellular transcription factors (reviewed 1989, 1993; Zahm et al., 1988; Zhou et al., 1994). Although
in Sodroski et al., 1992). Two different Tax-responsive the role of X in HBV pathogenesis is not clearly defined,
elements have been described in the HTLV-I LTR, includ- almost all infected individuals have antibodies to X
(Feitelson, 1992; Kay et al., 1985; Moriarty et al., 1985),
suggesting that it is expressed during the replication1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (713) 798-3590. E-mail: susanm@bcm.tmc.edu. cycle. The viral enhancer(I) serves as the X-responsive
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element in the HBV promoter (Spandau and Lee, 1988; al., 1995) into the vector pSG424 (Sadowski and Ptashne,
1989), which contains the coding sequence for aminoTwu and Schloemer, 1987). The X protein is frequently
termed a ‘‘promiscuous’’ transactivator as numerous tran- acids 1–147 of Gal4 followed by a polylinker. The X gene
was cloned in-frame into the SmaI site of the polylinker.scriptional regulatory sequences from heterologous vi-
ruses and cellular genes have been reported as targets LTRDAP-2 was constructed by cloning oligonucleotides
containing a mutant AP-2 binding site into the SmaI sitefor transactivation. X has been reported to transactivate
adenovirus, herpes simplex virus, human immunodefi- of pU3RCAT. This cloning disrupted the native AP-2 site
in the LTR and replaced it with a mutant element. Theciency virus, HTLV-I, HTLV-II, mouse mammary tumor
virus, Rous sarcoma virus, SV40, and Visna virus, as well sense strand of the mutant AP-2 oligonucleotide is
shown with the mutant bases underlined: HTLV mut AP-as a variety of cellular genes (reviewed in Rossner, 1992).
The X-responsive elements in these promoters include 2S 5*-CCCAAATATCCCTTGGGGGCTTAG-3*.
AP-1, AP-2, AP-3, and NF-kB sites, as well as HBV en-
Cells and transfectionshancer elements. Like Tax, the HBV X protein does not
bind DNA specifically and recent studies suggest that the HeLa cells were maintained in Dulbecco’s modified
X protein acts indirectly to activate transcription through essential medium (DMEM) supplemented with 10% fetal
cellular signaling pathways involving the serine/threo- calf serum (FCS). For transfections, 2 1 105 cells were
nine kinases, protein kinase C, and Raf-1 (Benn and seeded in 35-mm dishes. After 24 hr the medium was
Schneider, 1994; Cross et al., 1993; Kekule et al., 1993). replaced and approximately 5 hr later the cells were
In addition, the X protein is able to interact with a cellular transfected by the calcium phosphate method as de-
DNA repair protein (Lee et al., 1995), providing another scribed (Connor et al., 1993). The specific amounts of
means by which X may modify cellular replication pro- plasmids used in each transfection are provided in the
cesses. figure legends. Approximately 18 hr following transfec-
The results that follow demonstrate that the HBV X tion the medium was removed and replaced with fresh
protein can activate transcription of the HTLV-I LTR. An medium. Cells were harvested for CAT assays 48 hr fol-
X-responsive region (XRR) of the LTR was localized to lowing transfection.
nucleotides 0355 to 0276 and was shown to contain
an AP-2 binding site. Further, Tax and X synergistically CAT assays
activated transcription of the LTR; however, the AP-2
Cells were harvested and CAT assays were performedbinding site was not required for this synergy. These
as described (Connor et al., 1993). Briefly, cells wereresults suggest the possibility that the HBV X protein may
washed in phosphate-buffered saline and collected byaffect the level of HTLV-I gene expression in co-infected
scraping in TEN buffer (40 mM Tris, pH 7.8, 1 mM EDTA,cells.
150 mM NaCl). Cells were pelleted, resuspended in 0.25
M Tris, pH 7.8, and disrupted by three freeze/thaw cycles.MATERIALS AND METHODS
The amount of extract used in each CAT assay was se-
Plasmids lected so that the resulting conversion to acetylated
chloramphenicol would be less than 70%. Each experi-Expression constructs containing the HTLV-I Tax and
ment was repeated a minimum of two times. TLC platesGal-Tax genes under the control of the SV40 promoter
were quantitated using a Betagen blot analyzer. The per-have been described previously (Connor et al., 1993).
centage conversion of CAT to the acetylated form wasConstruction of the HTLV-I deletion constructs 10-1, 6-3,
calculated by dividing the cpm found in 14C-labeled ace-and 11-2 (Brady et al., 1987) and promoters containing
tylated chloramphenicol by the total of acetylated andgal4 binding sites, 11-2-35ASgalS and 6-2galSS (Conner
nonacetylated chloramphenicol. All data are reported aset al., 1993), have been described previously.
fold activation, which was calculated by dividing the per-5*LTR-CAT was constructed by PCR amplification of
centage CAT conversion of a particular sample by thethe 5* region of the HTLV-I LTR from a pU3RCAT (So-
percentage CAT conversion achieved with the corre-droski et al., 1984) template using the 5*LTR-S and 5*LTR-
sponding vector alone.AS primers. The primers were designed to convert the
ends of the resulting fragment to BglII sites with an inter-
Gel shift assays
nal PvuII site at the 3* end of the double-stranded PCR
product: 5*LTR-S, 5*-GACTCTAGATCTCATAGTTTACAT- Oligonucleotides encompassing nucleotides 0309 to
0326 in the HTLV-I LTR were synthesized with overhang-CTCC-3*; 5*LTR-AS, 5*-GGGCTGAGATCTCAGCTGACT-
TCTGTTTCTCGG-3*. The resulting PCR product was di- ing XbaI compatible ends using a Beckman Oligo1000
DNA synthesizer. The sequence of the sense strand oli-gested with BglII and cloned into the BglII site of pCAT-
Promoter (Promega), which contains the enhancer-less gonucleotide is HTLV AP-2S, 5*-CTAGCAAATATCCCC-
CGGGGGT-3*. Following synthesis, the oligonucleotidesSV40 promoter upstream of the CAT gene. Gal-X was
constructed by cloning the X-coding sequence (Lee et were annealed and labeled with [32P]dCTP using the
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fection of 0.5, 1, and 5 mg of X also resulted in dose-
dependent activation of the LTR with a maximum of 8-
fold activation. The 8-fold activation of the HTLV-I LTR by
X is typical of other X responsive promoters. While this
experiment demonstrates that HBV X can activate the
HTLV-I LTR in HeLa cells, X appears to be a weaker
activator of the HTLV-I LTR than Tax.
An X-responsive element resides in the 5* end of the
HTLV-I LTR
X-responsive elements have been mapped to NF-kB,
AP-1, AP-2, and AP-3 sites. The HTLV-I LTR does notFIG. 1. The HBV X protein activates the HTLV-I LTR. HeLa cells were
transfected with 5 mg of pU3RCAT reporter plasmid alone (h) or with contain any previously recognized AP-1, or AP-3 sites,
increasing concentrations (0.5, 1, 5 mg) of Tax (j) or X (É) expression although the location of putative AP-2 and NF-kB sites
plasmids as indicated. Fold activation was calculated by dividing the has been suggested (Numata et al., 1991; Nyborg et al.,
CAT activity of activated constructs by the basal activity of pU3RCAT.
1990). To determine which portion of the HTLV-I LTR was
involved in X activation, a series of LTR deletion mutants
was tested (Fig. 2A). As shown in Fig. 2B, Tax activatedKlenow fragment of DNA polymerase. The labeled, dou-
ble-stranded oligonucleotide (50,000 cpm/0.71 ng) was expression of the full-length LTR (pU3RCAT) as well as
two deletion mutants (10-1 and 6-3). The increased Taxincubated with 2 ml of HeLa nuclear extract (6.2 mg/ml),
1 mg of poly(dI–dC), and 6 ml of 51 reaction buffer (50 activation of the deletion mutants, as compared to the
full-length LTR, has been previously reported (Brady etmM HEPES, pH 7.9, 20% Ficoll, 250 mM KCl, 1 mM EDTA,
and 1 mM DTT). Buffer D (20 mM HEPES, pH 7.9, 100 al., 1987; Marriott et al., 1990) and could result from dele-
tion of a negative regulatory element combined with re-mM KCl, 12.5 mM MgCl2 , 17% glycerol, 1 mM EDTA, and
1 mM DTT) was added to each reaction to bring the total duced basal activities of the deletion mutants. As seen
previously, HBV X activated the full-length HTLV-I LTR.volume of buffer D plus nuclear extract to 18 ml. A 50-
fold molar excess of unlabeled competitor oligonucleo- In contrast, X activation of the deletion mutants was di-
minished in mutant 10-1 and could not be distinguishedtides was added to certain reactions as indicated. The
reactions were incubated for 20 min at room temperature. from basal activity in mutant 6-3. The 10-1 reporter has
deleted nucleotides 0355 to 0306 in the viral LTR rela-The antibody supershift experiment was performed by
adding the specified rabbit polyclonal antibody following tive to the transcription start site, while in the 6-3 con-
struct, additional nucleotides were deleted to 0242the initial 20-min incubation, then incubating for an addi-
tional 30 min at room temperature. The samples were (Brady et al., 1987). Thus, this result suggested that an
X-responsive element resides in the 5* region of the LTRseparated on a 5% nondenaturing polyacrylamide gel in
0.51 TBE (45 mM Tris-borate, 1 mM EDTA) at 150 V for between nucleotides 0355 and 0242. To test this possi-
bility, X transactivation of nucleotide sequences 0355 to2.5 hr. The gel was dried and exposed to Kodak XAR5
X-ray film for 9 hr at0707 with a screen. The AP-2 consen- 0276 from the LTR (5*LTR-CAT) was examined. Nucleo-
tides 0242 to 0276 were not included in this reportersus and mutant competitors as well as the anti-AP-2,
anti-AP-1, and anti-Sp1 antibodies were purchased from construct because they contain a portion of TRE-1. The
5*LTR-CAT reporter was not responsive to Tax but wasSanta Cruz Biotechnology Inc. The AP-1, AP-3, and Sp1
competitors were purchased from Stratagene. activated fourfold by HBV-X, demonstrating that an X re-
sponsive element resides between nucleotides 0355
and 0276 in the HTLV-I LTR. These nucleotides are thusRESULTS
referred to as the X-responsive region of the HTLV-I LTR.
HBV X protein transactivates the HTLV-I LTR
The nucleotide sequence of the XRR is shown in Fig. 2C.
Activation of the XRR by X protein is approximately 75%To investigate the possibility that the HBV X protein
may activate the HTLV-I LTR, HeLa cells were cotrans- of that observed with the full LTR, suggesting that se-
quences outside of the XRR may contribute to optimal Xfected with a plasmid encoding the HTLV-I LTR driving
chloramphenicol acetyl transferase (CAT) expression transactivation.
Visual inspection of the XRR for elements which had(pU3RCAT) and increasing concentrations of expression
vectors encoding either the HTLV-I Tax or the HBV X previously been recognized as X responsive, revealed a
sequence at position 0328 to 0320 which resembles anproteins. Both Tax and X genes were under the control
of the SV40 early promoter. Transfection of 0.5, 1, and 5 AP-2 binding site (Fig. 3A). To determine whether this
element functions as a specific AP-2 binding site, gelmg of Tax resulted in dose dependent activation of the
LTR with a maximum of 25-fold activation (Fig. 1). Trans- shift analysis was performed using a series of oligonu-
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FIG. 2. The X-responsive element resides in the 5* end of the LTR. (A) Diagram of reporter constructs used in this experiment. TRE-1 and TRE-
2 elements are shown as black and shaded rectangles, respectively. The position of the TATA box (⊥), transcription start site (r), and CAT reporter
gene ( ) is shown. Nucleotide numbering of the LTR relative to the transcription start site is shown above. (B) HeLa cells were transfected with
5 mg of the indicated reporter plasmid (pU3RCAT, 10-1, 6-3, 5*LTR-CAT) and either 1 mg of Tax (j) or 3 mg of X (É) expression plasmids. The basal
activity of each reporter was normalized to one and fold activation was calculated by dividing the CAT activity of activated constructs by their basal
activity. (C) Detailed diagram of the X responsive element in the HTLV-I LTR. LTR elements are depicted as described in A. The nucleotide sequence
of the X-responsive region of the LTR is shown at the bottom. The position of previously reported Ets1 and Myb binding sites is shown. An LTR
sequence containing 75% identity with a consensus AP-2 site is underlined.
cleotide competitors. When the 32P-labeled oligonucleo- was reduced when the reaction contained a 50-fold ex-
cess of the unlabeled probe or an oligonucleotide repre-tide probe representing the putative AP-2 binding site in
the HTLV-I LTR was mixed with HeLa nuclear extract a senting the consensus AP-2 binding site. A mutation in
the consensus AP-2 binding site which has previouslygel shift complex was formed. Formation of this complex
FIG. 3. Gel shift analysis of the X-responsive element in the HTLV-I LTR. (A) The nucleotide sequence of the HTLV-I LTR used as a probe is
shown (HTLV AP-2) as well as the sequences of competitor oligonucleotides: consensus AP-2, mutant AP-2, consensus AP-1, consensus AP-3, and
consensus SPl. The core element necessary for protein binding is boxed in the AP-2 and mutant AP-2 sequences. The HTLV AP-2 element showing
sequence conservation with the consensus AP-2 core element is underlined. (B) The 32P-labeled HTLV AP-2 probe was incubated alone (lane 1)
or with HeLa nuclear extract (lanes 2–8). A 50-fold molar excess of unlabeled oligonucleotide competitor was added to lanes 3–8 (lane 3, HTLV
AP-2; lane 4, consensus AP-2; lane 5, mutant AP-2; lane 6, consensus AP-1; lane 7, consensus AP-3; lane 8, consensus SPl). The position of the
specific protein complex is indicated by the arrow. The location of the free probe is also indicated. (C) The 32P-labeled HTLV AP-2 probe was
incubated alone (lane 1) or with HeLa nuclear extract (lanes 2–6). Antibodies against specific transcription factors were added to lanes 3–7 (lanes
3 and 7, anti-AP-2; lane 4, anti-SPl; lane 5, anti-CREB; lane 6, anti ATF-3). The positions of the specific protein complex and the supershifted complex
are indicated. The location of the free probe is also indicated.
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length LTR was activated 25-fold by Tax and 4-fold by X
(Fig. 5). When transfected together, Tax and X activated
transcription of the LTR 45-fold. To control for the possi-
ble effects of increased vector and promoter concentra-
tions in the transfection containing both Tax and X, a
plasmid expressing b-galactosidase under control of the
SV40 promoter was used to replace the appropriate
transactivator. No synergistic activity was observed with
either Tax and b-gal or X and b-gal. In addition, b-gal
activities were similar when transfected alone or when
transfected with Tax or X, demonstrating that neither pro-
tein affected levels of expression from the SV-40 pro-
moter under the conditions tested (data not shown).
These results demonstrate that HTLV-I Tax and HBV X
FIG. 4. The AP-2 binding site is required for X transactivation of the
proteins can specifically synergize to activate the HTLV-HTLV-I LTR. HeLa cells were transfected with 5 mg of the reporters
I LTR.pU3RCAT or LTRDAP-2 alone, or in combination with 1 mg of Tax or
3 mg of X expression plasmids. Fold activation was calculated as de-
scribed in the legend to Fig. 2. Synergistic activation of the HTLV-I LTR by Tax and X
does not require the XRR
been shown to abolish AP-2 binding did not compete Since Tax and X utilize distinct elements for indepen-
for complex formation. Three other transcription factor dent activation of LTR transcription, we examined the
binding site oligonucleotides (AP-1, AP-3, and Sp1) were possibility that the synergistic effect of Tax and X re-
similarly unable to compete for complex formation. These quired both response elements. Reporter constructs con-
results demonstrate that a specific protein complex can taining either functional Tax response elements and mu-
form on the HTLV-I probe and that this complex is likely tated X response elements (10-1, 6-3, 11-2, and LTRDAP-
to be AP-2. To confirm this result, a supershift assay was 2) or a functional X response element in the absence of
performed (Fig. 3B). Addition of anti-AP-2 antibody to the Tax response elements (5*LTR-CAT) were examined for
gel shift reactions caused the complex to shift to a slower synergistic activation. Each of the reporters containing a
mobility while antibodies directed toward three other functional Tax response element in the absence of an X
transcription factors (Sp1, CREB, and ATF-3) were unable response element were activated by Tax, failed to be
to supershift the complex (Fig. 3C). In the absence of activated by X, and displayed synergistic activation in the
nuclear extract, the AP-2 antibody did not affect the mo- presence of both proteins (Fig. 5). The reporter 5*LTR-
bility of the labeled probe. These results verify the identity CAT, containing a functional X response element in the
of the protein involved in the complex as AP-2. absence of Tax response elements, was activated by X,
failed to be activated by Tax, and did not display syner-
The AP-2 element is required for X transactivation of gistic activation in the presence of both proteins. These
the HTLV-I LTR results demonstrate that synergistic activation of the
HTLV-I LTR by Tax and X requires a Tax response ele-To directly determine whether the AP-2 element is in-
ment but does not require an X response element. Thus,volved in X transactivation of the HTLV-I LTR the element
the ability of X to activate transcription of the HTLV-Iwas mutated within the context of the complete LTR
LTR and its ability to work in combination with Tax to(LTRDAP-2). This mutation introduced a 2 base pair C
synergistically activate transcription may be separableto T change that was identical to the mutation which
activities.abolished AP2 binding in the previous experiment.
LTRDAP-2 was completely unresponsive to HBV-X but
DISCUSSIONretained responsiveness to Tax (Fig. 4). Thus, the binding
of AP-2 correlates with X transactivation of the HTLV-I The results described here demonstrate that the HBV
LTR and specifically, the AP-2 binding site located at X protein can transactivate the HTLV-I LTR through an0320 was required for X transactivation. element located in the 5* end of the LTR. This region of
the LTR contains an AP-2 binding site which is required
Tax and X synergistically activate the HTLV-I LTR
for X activation. In combination, Tax and X proteins syner-
gistically activate the LTR, although the synergy does notTax and X share many similar characteristics including
transforming properties, transcriptional activity, and an require the AP-2 binding site. Based on these results,
we propose that co-infection with HTLV-I and HBV mayinability to bind DNA specifically. Therefore, it was of
interest to determine whether these two transactivators influence the progression of HTLV-I-associated disease.
A direct analysis of the effect of HBV on HTLV-I replica-could cooperate in activation of the HTLV-I LTR. The full-
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FIG. 5. Tax and X synergistically transactivate the HTLV-I LTR. HeLa cells were transfected with 5mg of the indicated reporters alone, or in combination
with 0.5 mg of Tax or 3 mg of X expression plasmids as indicated. Fold activation was calculated as described in the legend to Fig. 2.
tion awaits the optimization of infectious HTLV-I and HBV native mechanisms of X transactivation which do not
require that X become associated with a promoter haveclones.
There are several possible mechanisms by which the been suggested. For example, X has been shown to af-
fect the affinity of AP-1 for DNA, possibly by modulatingHBV X protein could activate the HTLV-I LTR. The X pro-
tein may act directly on a sequence within the HTLV-I its phosphorylation state (Natoli et al., 1994). Supporting
this model, X has been shown to affect the activity ofLTR, although X does not appear to bind DNA specifically
(Faktor and Shaul, 1990; Rossner, 1992). It has previously cellular kinases (Benn and Schneider, 1994; Cross and
Rutter, 1993; Luber et al., 1993). Thus, it appears likelybeen reported that X activation may be mediated through
NF-kB, CREB/ATF, AP-1, AP-2, or AP-3 elements (Lucito that activation of the HTLV-I LTR by X protein occurs
through an indirect mechanism and may involve multipleand Schnieder, 1992; Maguire et al., 1991; Seto et al.,
1990; Twu et al., 1989). A potential NF-kB site has been elements within the LTR.
The ability of Tax and X to synergistically activate tran-identified within the TRE-2 region of the HTLV-I LTR, but
it is clear from studies presented here that this site is scription may involve cooperative interactions between
their two activation pathways. It has recently been dem-not sufficient for X activation (Fig. 2B). The TRE-1 ele-
ments within the HTLV-I LTR share identity with CREB onstrated that X can function as a coactivator in combina-
tion with a variety of potent activation domains (Haviv etand ATF binding sites and these proteins can bind the
TRE-1 elements. Although X has been shown to bind al., 1995), although Tax was not included in that study.
It is possible that X may provide a coactivator functionCREB/ATF-2 proteins (Maguire et al., 1991), our data
demonstrate that these elements are not sufficient for X for the Tax activation domain, resulting in the synergistic
activation of LTR transcription which is observed in thetransactivation of the HTLV-I LTR. No AP-1 or AP-3 ele-
ments have been identified within the HTLV-I LTR, al- presence of both proteins. As synergistic activation of
the HTLV-I LTR by Tax and X does not require the pres-though two AP-2 sites have been recognized at approxi-
mately 0180 and 0230 (Nyborg et al., 1990). These AP- ence of the X response element, it is possible that the
ability of X to modulate cellular serine/threonine kinases2 sites are not present in the 5* LTR construct which
was activated by X and the construct 6-3, which contains may increase the pool of phosphorylated transcription
factors available for Tax-mediated transactivation.these elements, was not efficiently activated by X, sug-
gesting that they are also not sufficient for maximal acti- Whereas these studies are of general interest due to
the insights they provide into basic transcription mecha-vation by X. However, an additional site containing a 6
of 8 nucleotide match with the AP-2 consensus sequence nisms, the finding that X and Tax synergistically activate
LTR transcription more specifically suggests that co-in-located within the X-responsive 5* region of the LTR was
identified in this study. We demonstrated that this se- fection by HTLV-I and HBV might lead to a more aggres-
sive HTLV-I infection and possibly affect the developmentquence does serve as a functional AP-2 binding site
which is both necessary and sufficient for X transactiva- of HTLV-I-associated disease. In a survey of 13 villages
in Papua, New Guinea, 3 of 13 (23%) serum samplestion of the HTLV-I LTR. It is possible that X may bind AP-
2 directly, forming a physical complex with enhanced which tested positive for HTLV-I were also positive for
HBV, demonstrating that co-infection with these two vi-transcriptional activity, as has been shown with X and
CREB/ATF family members (Maguire et al., 1991). Alter- ruses is relatively prevalent in this population (Yama-
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Gessain, A., Barin, F., Vernant, J. C., Gout, O., Maurs, L., Calendar, A.,guchi et al., 1993). In a study of HTLV-I and HBV infection
and DeThe, G. (1985). Antibodies to human T-lymphotropic virus typeamong Japanese blood donors, approximately 3% of
I in patients with tropical spastic paraparesis. Lancet 2, 407–410.
those positive for HTLV-I were also positive for HBV (Asa- Gitlin, S. D., Bosselut, R. Gegonne, A. Ghysdael, J. Brady. J. N. (1991).
kura et al., 1991). Both HTLV-I and HBV have been shown Sequence-specific interaction of the Ets1 protein with the long termi-
nal repeat of the human T-lymphotropic virus type I. J. Virol. 65, 5513–to infect T cells in vivo (Colucci et al., 1988; Davison et
5523.al., 1987; Laure et al., 1985; Zeldis et al., 1986), although
Gitlin, S. D., Dittmer, J., Shin, R. C., and Brady, J. N. (1993). Transcrip-it has not been determined whether the same cells are
tional activation of the human T-lymphotropic virus type I long termi-
infected with both viruses in co-infected individuals. This nal repeat by functional interaction of Tax1 and Ets1. J. Virol. 67,
study highlights the importance of future efforts to deter- 7307–7316.
Haviv, I, Vaizel, D., and Shaul, Y. (1995). The X protein of hepatitis Bmine the role of HTLV-I and HBV co-infection in the
virus coactivates potent activation domains. Mol. Cell. Biol. 15, 1079–pathogenesis of associated diseases.
1085.
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